8IY9 image
Entry Detail
PDB ID:
8IY9
EMDB ID:
Title:
Structure of Niacin-GPR109A-G protein complex
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-04-04
Release Date:
2024-03-06
Method Details:
Experimental Method:
Resolution:
3.37 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(o) subunit alpha
Mutations:G42D,E43N,A227D,G230D,I332A,V335I
Chain IDs:A
Chain Length:240
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Chain IDs:B
Chain Length:350
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Chain IDs:C (auth: G)
Chain Length:71
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:ScFv16 (Antibody Fragment)
Chain IDs:D (auth: H)
Chain Length:248
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Description:Hydroxycarboxylic acid receptor 2
Chain IDs:E (auth: R)
Chain Length:419
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Structure-guided engineering of biased-agonism in the human niacin receptor via single amino acid substitution.
Nat Commun 15 1939 1939 (2024)
PMID: 38431681 DOI: 10.1038/s41467-024-46239-2

Abstact

The Hydroxycarboxylic acid receptor 2 (HCA2), also known as the niacin receptor or GPR109A, is a prototypical GPCR that plays a central role in the inhibition of lipolytic and atherogenic activities. Its activation also results in vasodilation that is linked to the side-effect of flushing associated with dyslipidemia drugs such as niacin. GPR109A continues to be a target for developing potential therapeutics in dyslipidemia with minimized flushing response. Here, we present cryo-EM structures of the GPR109A in complex with dyslipidemia drugs, niacin or acipimox, non-flushing agonists, MK6892 or GSK256073, and recently approved psoriasis drug, monomethyl fumarate (MMF). These structures elucidate the binding mechanism of agonists, molecular basis of receptor activation, and insights into biased signaling elicited by some of the agonists. The structural framework also allows us to engineer receptor mutants that exhibit G-protein signaling bias, and therefore, our study may help in structure-guided drug discovery efforts targeting this receptor.

Legend

Protein

Chemical

Disease

Primary Citation of related structures